Darzalex® (daratumumab) – Expanded indication
June 16, 2017 - Janssen announced the FDA approval of Darzalex (daratumumab), in combination with Pomalyst® (pomalidomide) and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including Revlimid® (lenalidomide) and a proteasome inhibitor (PI).
Top